Vincerx Pharma, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2023-09-13: Study NCT06034275; Company role Lead sponsor; Phase Phase 1; Status Recruiting.
- 2023-01-24: Study NCT05712889; Company role Lead sponsor; Phase Phase 1; Status Completed.
- 2021-12-16: Study NCT04978779; Company role Lead sponsor; Phase Phase 1; Status Terminated.
- 2016-02-10: Study NCT02635672; Company role Lead sponsor; Phase Phase 1; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2023-09-13 | NCT06034275 Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies | Lead sponsor | Phase 1 | Recruiting | Acute Myeloid Leukemia; B-cell Acute Lymphoblastic Leukemia; High-risk Myelodysplastic Syndrome | 36 | 2025-12-31 |
| 2023-01-24 | NCT05712889 Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer | Lead sponsor | Phase 1 | Completed | Neoplasms | 29 | 2024-10-10 |
| 2021-12-16 | NCT04978779 A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome | Lead sponsor | Phase 1 | Terminated | Relapsed Non Hodgkin Lymphoma; Chronic Lymphocytic Leukemia; Refractory Chronic Lymphocytic Leukemia; Richter Syndrome; MYC Amplification; MYC Overexpression; MYC Translocation | 6 | 2023-05-26 |
| 2016-02-10 | NCT02635672 Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | Lead sponsor | Phase 1 | Completed | Neoplasms | 110 | 2024-11-11 |